Terapi Saat Ini untuk Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Sebuah Literature Review

Ilsa Hunaifi Hunaifi; Teguh Budi  Wicaksono; Gede Rama Hardy  Nugraha; Rizka Ayu  Maulida; Rima Cahyati  Kusumadewi; Rukmanggana Satya  Pratiwi; Annisa Risqi  Amaliya; Ghina Shadrina Rienti  Sepestian

doi:10.29303/jstl.v10i3.619

Authors

Ilsa Hunaifi Hunaifi Departemen Neurologi, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram
Teguh Budi Wicaksono Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram
Gede Rama Hardy Nugraha Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram
Rizka Ayu Maulida Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram
Rima Cahyati Kusumadewi Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram
Rukmanggana Satya Pratiwi Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram
Annisa Risqi Amaliya Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram
Ghina Shadrina Rienti Sepestian Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Mataram

DOI:

https://doi.org/10.29303/jstl.v10i3.619

Keywords:

CIDP, Therapy, Hematopoietic Stem Cells, Spinal Cord Stimulation

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease. The European Academy of Neurology recommends treatment using corticosteroids, immunoglobulin, plasma exchange, & other treatments as treatment options for chronic inflammatory demyelinating polyradiculoneuropathy. However, several studies in recent years have shown that there is potential in the treatment of chronic inflammatory demyelinating Polyradiculoneuropathy. The aim of this literature review is to provide the latest therapy for chronic inflammatory demyelinating polyradiculoneuropathy based on guidelines as well as other information therapy alternatives. The method used in this literature review uses searches in several databases. The results of several studies show the development of chronic inflammatory demyelinating polyradiculoneuropathy therapy both pharmacologically & non-pharmacologically. The development of therapy for chronic inflammatory demyelinating polyradiculoneuropathy, namely hematopoietic stem cells & spinal cord stimulation, shows potential as a therapeutic option for patients with chronic inflammatory demyelinating polyradiculoneuropathy.

References

Bijaksono, Y. H. (2021). Chronic Inflammatory Demyelinating Polyradiculopathy. IX(1), 1257–1264. https://e-journal.upr.ac.id/index.php/JK/article/view/2865

Bril, V., Hadden, R. D. M., Brannagan, T. H., 3rd, Bar, M., Chroni, E., Rejdak, K., Rivero, A., Andersen, H., Latov, N., Levine, T., Pasnoor, M., Sacconi, S., Souayah, N., Anderson-Smits, C., Duff, K., Greco, E., Hasan, S., Li, Z., Yel, L., & Ay, H. (2023). Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial. Journal of the peripheral nervous system : JPNS, 28(3), 436–449. https://doi.org/10.1111/jns.12573

Brun, S., de Sèze, J. and Muller, S. (2022) ‘CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention’, Immuno, 2(1), pp. 118–131. doi: 10.3390/immuno2010009.

Brun, S., de Sèze, J., & Muller, S. (2022). CIDP: Current treatments and identification of targets for future specific therapeutic intervention. Immuno, 2(1), 118–131. https://doi.org/10.3390/immuno2010009

Burman, J., Tolf, A., Hägglund, H. and Askmark, H. (2018). Autologous haematopoietic stem cell transplantation for neurological diseases. Journal of Neurology, Neurosurgery & Psychiatry, [online] 89(2), pp.147–155. doi:https://doi.org/10.1136/jnnp-2017-316271.

Cohen, J.C. and Lewis, R.A. (2020) ‘Rituximab for chronic inflammatory demyelinating polyneuropathy—a potential therapeutic option’, Muscle & Nerve, 61(5), pp. 549–551. doi:10.1002/mus.26871.

Fehmi, J., Bellanti, R., Misbah, S. A., Bhattacharjee, A., & Rinaldi, S. (2023). Treatment of CIDP. Practical neurology, 23(1), 46–53. https://doi.org/10.1136/pn-2021-002991

Feyen, L., Schaub, C., Zimmermann, J., & Nitsch, L. (2023). Parameters Associated with the Required Drug Dose of Intravenous Immunoglobulin in Stable Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neurology international, 15(1), 405–414. https://doi.org/10.3390/neurolint15010027

Garcia K, Wray JK, Kumar S. Spinal Cord Stimulation. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553154/

Giacobbe, A., Patel, M., Heller, S., & Chuquilin, M. (2020). Treatment-resistant CIDP in an IgG Tubulin Autoantibody Positive Patient: case report and review of the literature. RRNMF Neuromuscular Journal, 1(5), 20-24. https://doi.org/10.17161/rrnmf.v1i5.14547

Godelaine, J., Chitale, Y., De Moor, B., Mathieu, C., Ancheva, L., Van Damme, P., Claeys, K. G., Bossuyt, X., Carpentier, S., & Poesen, K. (2023). Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neurology(R) neuroimmunology & neuroinflammation, 10(6), e200162. https://doi.org/10.1212/NXI.0000000000200162

Hu, J., Sun, C., Lu, J., Zhao, C., & Lin, J. (2022). Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. In Journal of Neurology (Vol. 269, Issue 3). https://doi.org/10.1007/s00415-021-10646-y

Jiao, L., Xiang, Y., Li, S., Zhang, F., Ruan, X., & Guo, S. (2020). Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155. Journal of neuroimmunology, 345, 577280. https://doi.org/10.1016/j.jneuroim.2020.577280

Koike, H. and Katsuno, M. (2020) ‘Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy’, Neurology and Therapy, 9(2), pp. 213–227. doi: 10.1007/s40120-020-00190-8.

Lehmann, H. C., Burke, D., & Kuwabara, S. (2019). Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. Journal of neurology, neurosurgery, and psychiatry, 90(9), 981–987. https://doi.org/10.1136/jnnp-2019-320314

Masson-Roy, J., Breiner, A., Warman-Chardon, J., Pringle, C.E., Allan, D., Bredeson, C., Huebsch, L., Kekre, N., Michael Lee Kennah, Martin, L., McDiarmid, S., Sultan Altouri, Atkins, H. and Bourque, P.R. (2021). Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Canadian journal of neurological sciences, 48(6), pp.1–7. doi:https://doi.org/10.1017/cjn.2021.30.

Mostofi A, Tavakkoli M, Bedran H, Nirmalananthan N, Pereira EAC. Spinal cord stimulation in the treatment of neuropathic pain in chronic inflammatory demyelinating polyneuropathy. J Clin Neurosci. 2019 Sep;67:255-257. doi: 10.1016/j.jocn.2019.06.006. Epub 2019 Jun 17. PMID: 31221583.

Muller, S. (2022). CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention. Immuno, 2(1), 118–131. https://doi.org/10.3390/immuno2010009

Nasseri, M. and Majjhoo, A. (2020) ‘Spinal cord stimulation can provide significant relief to patients with neuropathic pain caused by CIDP (1195)’, Neurology, 94(15_supplement). doi:10.1212/wnl.94.15_supplement.1195.

Ponnala, M., Mullen, B., Nawab, K., Ullah, S., Khan, S., Ali, F., Ponnala, M., Mullen, B., Nawab, K., Ullah, S., Khan, S. and Ali, F. (2023). Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Overview, Treatment, and a Case Study. Cureus, [online] 15(10). doi:https://doi.org/10.7759/cureus.47475.

Rocha, R., Correia, F., Santos, A., & Martins, J. (2020). Adjuvant rituximab improves sensory ataxia in CIDP-related Sjögren syndrome. BMJ case reports, 13(8), e234681. https://doi.org/10.1136/bcr-2020-234681

Task Force—Second revision’, European Journal of Neurology, 28(11), pp. 3556–3583. doi: 10.1111/ene.14959.

Van den Bergh, P. Y. K. et al. (2021) ‘European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint

Van den Bergh, P.Y.K., Doorn, P.A., Hadden, R.D.M., Avau, B., Vankrunkelsven, P., Allen, J.A., Attarian, S., Blomkwist‐Markens, P.H., Cornblath, D.R., Eftimov, F., Goedee, H.S., Harbo, T., Kuwabara, S., Lewis, R.A., Lunn, M.P., Nobile‐Orazio, E., Querol, L., Rajabally, Y.A., Sommer, C. and Topaloglu, H.A. (2021). European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. Journal of the Peripheral Nervous System, 26(3), pp.242–268. doi: https://doi.org/10.1111/jns.12455.

Verhamme, C. (2024). Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives. Therapeutics and Clinical Risk Management, Volume 20, 111–126. https://doi.org/10.2147/tcrm.s360249.